MSK-21339
Empathic Communication Skills Training to Reduce Lung Cancer Stigma
This study will evaluate Empathic Communication Training (ECT), a new training for cancer care providers. ECT aims to improve care providers’ awareness and understanding of lung cancer stigma while developing their skills to communicate empathically with patients. We will try to find out whether ECT improves empathic communication skills needed to provide care that limits lung cancer stigma experienced by patients. The study will also provide information about whether ECT in care providers is associated with improved outcomes for lung cancer patients. For example, we will look at whether ECT reduces lung cancer stigma and improves patients’ experiences with the care they receive for their cancer.
Lung cancer stigma is when people say or do things that make patients feel like they deserved to get lung cancer. Because patients who report experiencing lung cancer stigma have higher rates of depression, anxiety, physical symptoms, delays in seeking medical care, and avoiding tobacco cessation support, it’s important to find ways to increase empathic communication by cancer care providers and decrease lung cancer stigma in the healthcare setting. Currently, there are no standard care provider trainings that focus on teaching empathic communication to cancer care providers. This study will help us develop a training that may reduce lung cancer stigma and result in better treatment experiences for patients.
Principle Investigator: Matthew Puc, MD
SWOG LUNGMAP
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)” (NCT 03851445)
Patients are being asked to take part in this research study because they have non-small cell lung cancer. They are asked to submit a tumor sample to test for specific genes and proteins. Based on the test results, they will be assigned to one of the treatment sub-studies.
The study is being done to find out if a targeted or immunotherapy treatment will have an effect on specific genes and proteins in the tumor.
The purpose of this study screening step is to test specific genes and proteins in the tumor sample.
Pre-Screening: Patients are considered in pre-screening if they are currently receiving cancer treatment. They will continue with the current treatment as long as it is continuing to help them. However, if the tumor begins to grow, pre-screening will make it easier for them to take part in one of the treatment studies matching the tumor to an appropriate study drug.
Screening: Patients are considered in screening if they have experienced tumor growth.
Based on the test results, they will be assigned to one of the treatment studies. We do not know how accurate this screening will be in matching the tumor type to a drug to treat the tumor.
We expect that between 750 and 1250 patients will be screened for this study each year. We also expect that about 400 to 500 patients per year will go on to receive treatment on one of the assigned treatment studies.
Click Here for more information
Principle Investigator: James Lee, M.D.
SWOG S1900E
A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study) (NCT 04625647)
There are several investigational treatments that are being tested in various sub-studies as part of this overall study. Patients have already received the information on their biomarker testing from their participation on the LUNGMAP screening study. They have been assigned to this treatment sub-study because the tumor sample is positive for the biomarker known as KRASG12C mutation. The presence of the KRASG12C mutation is one of the main reasons that the cancer has the ability to grow and spread. For this treatment study, patients will be assigned to treatment with an investigational drug called AMG 510, which targets the KRASG12C mutation.
This study is being done to answer the following question:
Can we lower the chance of the growth or spread of KRASG12C-mutated advanced non-squamous non-small cell lung cancer by using the study drug AMG 510?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach for participants who are not in a study is treatment with other cancer directed treatments such as chemotherapy or immunotherapy.
Click Here for more information
Principle Investigator: James Lee, M.D.
SWOG S1900G
A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
This study is part of a larger research study that tests many different treatments for advanced non-small cell lung cancer. Based on the results of tumor genetic testing, patients have been assigned to this treatment study because their tumor sample has MET gene changes, in addition to the EGFR gene changes that were previously known. For this treatment study, they will get one of the following combinations of drugs for treatment. The drug combinations are:
• INC280 (capmatinib) and osimertinib OR
• INC280 (capmatinib) and osimertinib with ramucirumab
The purpose of this study is to compare treatment with INC280 (capmatinib) and osimertinib with or without ramucirumab. The study doctors want to see if the study drugs may work for people who have been previously treated for advanced non-small cell lung cancer and have a tumor(s) that has MET gene changes, in addition to the EGFR gene changes that were previously known. The presence of changes in the EGFR and MET genes is one of the main reasons that the cancer can grow and spread. Adding ramucirumab to the combination of INC280 (capmatinib) and osimertinib could shrink the cancer.
This study will help the study doctors find out if the approach to treating this type of cancer with INC280 (capmatinib), osimertinib, and ramucirumab is better, the same, or worse, than INC280 (capmatinib) and osimertinib alone. To decide if it is better, the study doctors will be looking to see if INC280 (capmatinib), osimertinib and ramucirumab are better at preventing the cancer from growing compared to INC280 (capmatinib) and osimertinib alone.
Click Here for more information
Principle Investigator: James Lee, M.D.
SWOG S1900K
S1900K, “A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)”
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.
Click Here for more information
Principle Investigator: James Lee, MD
Contacts for Participation in Clinical Trials:
Virtua Samson Cancer Center
Theresa Carducci, MSN, RN, BA, CCRP
Protocol Coordinator, Cancer Registry & Research
(856) 206-4721
tcarducc@virtua.org
Virtua Voorhees
Maria Jenkins, CCRP
Clinical Research Coordinator
(856) 247-7396
mdjenkins@virtua.org
Barbara Dillon, MSN, RN
Clinical Research Nurse
(856) 247-7395
bdillon@virtua.org